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Psoriasis Group of the Spanish
Academy of Dermatology and
Venereology (AEDV)
Recomendaciones del Grupo de Psoriasis de la
AEDV sobre el manejo de la consulta de
psoriasis durante la pandemia por COVID-19
To  the  Editor:
East  respiratory  syndrome,  COVID-19)  enable  us  to  sugge
that  the  risk  of  severe  manifestations  and  complications  o
COVID-19  is  no  greater  in  immunodepressed  patients  than  
the  general  population.
The  main  interleukins  (IL)  involved  in  the  pathogenes
of  psoriasis  (tumor  necrosis  factor  [TNF]  alfa,  IL-17,  and  I
23)  have  not  been  proven  to  affect  the  course  of  the  vir
infection,  although  they  could  be  involved  in  the  onset  o
the  cytokine  storm,  which  is  associated  with  the  severity  o
the  infection.  Therefore,  at  least  in  terms  of  pathogenesi
specific  inhibition  of  these  proteins  does  not  seem  to  imp
a  risk  with  respect  to  the  clinical  course  of  patients  takin
specific  immunomodulators.  The  impact  of  broad-spectru
immunomodulators  (methotrexate,  ciclosporin)  and  the































of  patients  with  psoriasis  are  shown  in  Table  1.
Psoriasis Clinic During the SARS-CoV-2
Pandemic6
In-person  specialist  psoriasis  clinic
The  conditioning  factors  and  restrictions  affecting  in-person
visits  to  the  specialist  psoriasis  clinic  will  be  those  that  are
appropriate  and  acknowledged  for  any  in-person  visit  to  the
dermatology  clinic  while  the  pandemic  lasts  (recommenda-
tions  of  the  institutions  themselves  and  of  the  AEDV).
Specialist  psoriasis  clinic  online
The  new  situation  brought  about  by  the  COVID-19  pan-
demic,  where  in-person  visits  are  expected  to  be  restricted,
could  provide  an  opportunity  for  the  development  and
appropriate  adaptation  of  complementary  strategies  (e.g.,
telemedicine,  in  the  screening,  management,  and  follow-up
of  psoriasis).
The  activities  that  each  unit  will  now  address  online
should  preferably  be  supervised  by  the  professionals  who  see
patients  at  the  in-person  visits  and  have  appropriate  knowl-
edge  and  experience  in  the  management  of  these  patients.
An  in-person  approach  should  continue  to  be  used,  at
least  for  the  initial  visits  or  until  the  skin  disease  is  well-
controlled.
Online  visits  could  be  alternated  with  in-person  visits  for
the  follow-up  of  well-managed  patients  whose  disease  is
controlled  with  the  treatment  prescribed  at  the  in-person
visits.
Therefore,  we  believe  that  it  would  be  of  interest  to
st
r
Infection  by  the  coronavirus  SARS-CoV-2  and  the  assoc
ated  disease,  COVID-19,  constitute  a  serious  public  healt
problem.  Considerable  uncertainty  surrounds  the  way  
which  this  problem  will  affect  inflammatory  diseases  suc
as  psoriasis  and,  in  particular,  patients  treated  with  sele
tive  immunomodulators  and  immunosuppressants.  Base
on  the  scarce  scientific  evidence  available  and  consisten
with  the  position  of  other  national  and  international  sc
entific  societies  (European  Academy  of  Dermatology  an
Venereology-Skin  Inflammation  and  Psoriasis  Internation
Network,  International  Psoriasis  Council,  American  Academ
of  Dermatology),1--3 the  Psoriasis  Group  of  the  Spanis
Academy  of  Dermatology  and  Venereology  (AEDV)  issued  
statement  through  the  AEDV  (GPs-COVID-19)4 with  the  ai
of  guiding  dermatologists  who  treat  psoriasis,  especially  
cases  where  patients  are  receiving  treatment  or  are  abou
to  initiate  treatment  with  selective  immunomodulators  o
immunosuppressants.1,2
The  SARS-CoV-2  pandemic  has  affected,  and  will  con
tinue  to  affect,  at  least  for  some  time,  the  managemen
of  patients  with  psoriasis  and  the  functioning  of  speciali
psoriasis  clinics.  Given  that  the  situation  is  gradually  com
ing  under  control,  it  is  worth  considering  the  conditions  fo
and  limitations  to  resuming  care  services  in  these  clinic
in  a  scenario  where  the  virus  continues  to  circulate,  wit
occasional  or  seasonal  exacerbations.
In  order  to  minimize  risk  for  and  maximize  benefits  t
patients  and  optimize  the  functioning  of  psoriasis  clinics,  th
Psoriasis  Group  has  developed  a  series  of  recommendation
based  on  scientific  evidence  and  on  recommendations  fro
other  scientific  societies.
In  any  case,  whether  or  not  these  recommendations  ar
applied  will  depend  on  scientific  evidence  and  the  progre
of  the  pandemic.
Recommendations
Patient  Management
Data  available  on  previous  and  current  outbreaks  of  coron
avirus  infection  (severe  acute  respiratory  syndrome,  Middle
 Please cite this article as: Belinchón I, Puig L, Ferrándiz L, de
la Cueva P, Carrascosa JM. Recomendaciones del Grupo de Psoriasis
de la AEDV sobre el manejo de la consulta de psoriasis durante la
pandemia por COVID-19. Actas Dermosifiliogr. 2020;111:803--805.
e
llset  out  the  main  uses  of  teledermatology  in  the  speciali
psoriasis  clinic  (Table  2).
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able  1  Recommendations  for  Patients  With  Psoriasis  During  the  COVID-19  Era.
 general,  patients  with  psoriasis  can  continue  their  treatment  during  the  COVID-19  pandemic  in  order  to  avoid  flare-ups  that
would directly  affect  the  patient  and  necessitate  greater  use  of  health  care  resources.
mall-molecule  immunosuppressants  and  biologics  should  generally  be  suspended  if  a  patient  is  suspected  of  having  active
COVID-19 infection.  Initiating  these  treatments  in  cases  of  active  infection  is  contraindicated.
 a  patient  lives  in  areas  with  a  high  incidence  of  COVID-19  or  is  in  close  contact  with  confirmed  cases,  temporary  suspension
of some  selective  immunomodulators  or  immunosuppressants  should  be  considered----taking  into  account  factors  such  as  age
and comorbid  conditions----until  the  infection  has  been  confirmed  or  ruled  out.
here is  no  evidence----or  restriction  to  date----with  respect  to  the  use  of  topical  treatments  in  the  management  of  patients
with psoriasis.
e  currently  lack  data  on  the  impact  of  psoriasis  therapy  on  susceptibility  to  or  severity  of  COVID-19.  Therefore,  health
professionals should  be  guided  by  their  previous  clinical  experience  and  their  understanding  of  the  mechanism  of  action  of
the treatment  they  prescribe.5
he  new  situation  brought  about  by  the  pandemic  may  affect  the  advisability  of  and  restrictions  associated  with
phototherapy  as  an  option  for  treatment  of  psoriasis.  The  Photobiology  Group  of  the  Spanish  Academy  of  Dermatology  and
Venereology  has  drafted  a  specific  document  in  this  area.
able  2  Main  Uses  of  Teledermatology  in  a  Specialist  Psoriasis  Unit.
creening  of  patients  in  order  to  evaluate  the  need  for  in-person  care  in  the  psoriasis  unit.  The  most  efficient  approach  in  this
case is  store-and-forward  teledermatology,  which  is  based  on  clinical  images  taken  in  the  health  center  and  requested  by
the family  physician.  Thus,  a  virtual  screening  appointment  makes  it  possible  to  identify  patients  with  moderate  to  severe
psoriasis who  are  candidates  for  systemic  treatment  or  phototherapy  and  can  be  seen  at  an  in-person  visit.  The  general
evaluation of  the  patient  should  take  into  account  the  impact  on  quality  of  life.
ollow-up  of  the  response  to  therapy  via  direct  teledermatology  between  physician  and  patient,  with  digital  images  taken  by
the patient  or  via  a  video  visit.  The  optimal  approach  should  include  an  online  history,  access  to  additional  tests  via  the
online history,  electronic  prescription,  and  basic  additional  tests  in  the  hospital  or  primary  care  center.
eporting of  incidents.  In  the  case  of  chronically  ill  patients,  teledermatology  is  also  useful  for  early  reporting  of  incidents
associated with  the  disease  (e.g.,  loss  of  response,  early  onset  of  comorbid  conditions)  or  with  treatments  (e.g.,  detection
of toxicity,  dispensing  incidents).  The  patient  should  be  able  to  contact  the  psoriasis  unit  without  having  to  travel,
according to  well-established  protocols,  and  using  any  means  of  communication  (e.g.,  telephone,  direct  virtual  consultation
with images  sent  by  the  patient,  app)  that  enables  a  suitable  response.  Reporting  should  fulfill  the  requirements  of
confidentiality,  encryption,  and  connection  with  the  computer  system  set  out  by  the  individual  health  service.
eledermatology  models  should  always  be  supported  by  guaranteed  in-person  care.  Therefore,  irrespective  of  the  stage  of
care, patients  will  benefit  from  in-person  or  virtual  visits  depending  on  the  modality  that  best  meets  their  needs  and  their
personal, occupational,  and  social  situation.
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Paniculitis eosinofílica secundaria a infección
por COVID-19
To  the  Editor
Within  just  3  months  of  the  detection  in  Wuhan  in  December
2019  of  the  first  cases  of  pneumonia  caused  by  a  novel  coron-
avirus,  the  scale  of  this  outbreak  has  increased  to  pandemic
proportions.  As  the  number  of  cases  increased,  new  respi-
ratory,  neurological,  digestive,  and  dermatological  clinical
manifestations  were  also  reported.1
A  29-year-old  Colombian  woman  with  no  relevant  his-
tory  was  seen  at  our  emergency  department  for  skin  lesions
that  had  appeared  1  week  earlier.  She  had  cough  and
fever  that  had  begun  20  days  earlier  and  for  which  she
was  not  being  treated.  She  reported  no  dyspnea  and  her
baseline  oxygen  saturation  was  97%.  A  laboratory  workup
revealed  the  following:  D-dimer,  1  790.0  ng/mL;  lympho-
cytes,  1  500/L; lactate  dehydrogenase,  202  U/L;  C-reactive
protein  <0.5  mg/L.  Chest  x-ray  was  normal.  Polymerase
chain  reaction  analysis  of  a  pharyngeal  swab  was  positive
for  SARS-CoV-2.
Physical  examination  revealed  the  presence  of  erythe-
matous  or  brownish  subcutaneous  nodular  lesions  (1--4  cm).













She  was  hospitalized  for  observation,  and  began
treatment  with  ceftriaxone,  enoxaparin,  and  hydroxychloro-
quine.  Betamethasone  cream  was  prescribed  for  the  skin
lesions.  The  patient’s  condition  improved  markedly  within  a
few  days,  after  which  she  was  discharged  from  hospital  and
isolated  at  home.
Eosinophilic  panniculitis  is  a  very  rare  form  of  panniculi-
tis.  It  affects  women  more  frequently  than  men  (3:1  ratio),
and  its  incidence  peaks  in  the  third  and  sixth  decades  of
life.2 It  is  a  reactive  process  secondary  to  a  range  of  stimuli,
h
lesions,  which  were  located  on  the  anterior  and  later
aspects  of  the  legs  (Fig.  1)  and  on  the  thighs,  forearms,  an
left  shoulder,  were  itchy  and  painful  on  palpation.
Skin  biopsy  of  a  lesion  on  the  right  leg  showed  n
alterations  in  the  epidermis.  The  superficial  and  deep  de
mis  contained  perivascular  inflammatory  infiltrate  (Fig.  2
which  reached  the  subcutaneous  tissue  and  displaye
a  predominantly  lobular  pattern  (Fig.  3A).  This  infi
trate  consisted  of  lymphocytes,  histiocytes,  and  numerou
eosinophils  (Fig.  3B).  Leukocytoclasia  was  evident.  Flam
figures  were  absent,  and  subcutaneous  involvement  wa
superficial,  without  fibrosis.  Blood  extravasation  withou
vasculitis  was  observed.
Based  on  these  findings,  the  patient  was  diagnosed  wit
eosinophilic  panniculitis  secondary  to  COVID-19  infection. Please cite this article as: Leis-Dosil VM, Sáenz Vicente A, Lorido-
Cortés MM. Paniculitis eosinofílica secundaria a infección por COVID-
19. Actas Dermosifiliogr. 2020;111:805--806.
inFigure  1  Nodular  lesion  (2  cm  in  diameter)  with  a  brownis
surface  located  on  the  outer  aspect  of  the  right  leg.
Figure  2  Panoramic  image  of  the  biopsy  (hematoxylin-eos
staining).  The  epidermis  is  preserved.  Note  the  perivascular  and
periadnexal  inflammatory  infiltrate  in  the  dermis  that  extends
to the  subcutaneous  tissue.
